These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20578982)

  • 1. New insights of CTLA-4 into its biological function in breast cancer.
    Mao H; Zhang L; Yang Y; Zuo W; Bi Y; Gao W; Deng B; Sun J; Shao Q; Qu X
    Curr Cancer Drug Targets; 2010 Nov; 10(7):728-36. PubMed ID: 20578982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
    Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expressions of Fas, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors].
    Bi Y; Wei L; Mao HT; Zhang L; Zuo WS
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):749-53. PubMed ID: 19173804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
    Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
    J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.
    Toussirot E; Saas P; Deschamps M; Pouthier F; Perrot L; Perruche S; Chabod J; Tiberghien P; Wendling D
    Arthritis Res Ther; 2009; 11(4):R101. PubMed ID: 19570209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD; Li L; Fan YY; Wu CY
    Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.
    Palmisano GL; Tazzari PL; Cozzi E; Bolognesi A; Polito L; Seveso M; Ancona E; Ricci F; Conte R; Stirpe F; Ferrara GB; Pistillo MP
    Clin Exp Immunol; 2004 Feb; 135(2):259-66. PubMed ID: 14738454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Regulatory T Cell-Related Markers (FOXP3, CTLA-4 and GITR) by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer.
    Khalife E; Khodadadi A; Talaeizadeh A; Rahimian L; Nemati M; Jafarzadeh A
    Asian Pac J Cancer Prev; 2018 Nov; 19(11):3019-3025. PubMed ID: 30484986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma.
    Matsuura K; Yamaguchi Y; Ueno H; Osaki A; Arihiro K; Toge T
    Cancer; 2006 Mar; 106(6):1227-36. PubMed ID: 16475148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production.
    Kosmaczewska A; Frydecka I; Boćko D; Ciszak L; Teodorowska R
    Br J Haematol; 2002 Jul; 118(1):202-9. PubMed ID: 12100149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro-Stimulated IL-6 Monocyte Secretion and In Vivo Peripheral Blood T Lymphocyte Activation Uniquely Predicted 15-Year Survival in Patients with Head and Neck Squamous Cell Carcinoma.
    Aarstad HH; Vintermyr OK; Ulvestad E; Kross K; Heimdal JH; Aarstad HJ
    PLoS One; 2015; 10(6):e0129724. PubMed ID: 26079381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced CTLA-4 protein and messenger RNA expression in umbilical cord blood T lymphocytes.
    Miller RE; Fayen JD; Mohammad SF; Stein K; Kadereit S; Woods KD; Sramkoski RM; Jacobberger JW; Templeton D; Shurin SB; Laughlin MJ
    Exp Hematol; 2002 Jul; 30(7):738-44. PubMed ID: 12135671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients.
    Llanes-Fernández L; Arango-Prado Mdel C; Alcocer-González JM; Guerra-Yi ME; Franco-Odio S; Camacho-Rodríguez R; Madrid-Marina V; Tamez-Guerra R; Rodríguez-Padilla C
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):255-64. PubMed ID: 18651178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro.
    Tiittanen M; Huupponen JT; Knip M; Vaarala O
    Diabetes; 2006 Dec; 55(12):3446-54. PubMed ID: 17130491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Study of Interleukin-2 Production and Nck Adaptor Molecule Gene Expression in Systemic Lupus Erythematosus Patients.
    Towiwat P; Buttham B
    J Med Assoc Thai; 2017 Apr; 100(4):396-402. PubMed ID: 29911835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
    J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CTLA-4 molecule in peripheral blood T lymphocytes from patients with systemic lupus erythematosus.
    Liu MF; Liu HS; Wang CR; Lei HY
    J Clin Immunol; 1998 Nov; 18(6):392-8. PubMed ID: 9857283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
    Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
    Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of interleukin-6 in mitogenic T-cell activation: detection of interleukin-2 heteronuclear RNA by polymerase chain reaction.
    Walz G; Stevens C; Zanker B; Melton LB; Clark SC; Suthanthiran M; Strom TB
    Cell Immunol; 1991 May; 134(2):511-9. PubMed ID: 1827050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.